PharmaFocus Today – Page 279 – media

Sage Therapeutics Fires 40% Of Staff after FDA Rejected MDD Bid

Sage Therapeutics will reduce its workforce by 40% following the US Food and Drug Administration’s (FDA) rejection of its drug Zurzuvae (zuranolone) in adults with major depressive disorder (MDD). The US-based company will pause some undisclosed early-stage programs and focus instead on the refinement of its compounds SAGE-718 and SAGE-324, per the 31 August announcement. Sage’s leadership will also change with the departure of the current chief scientific officer (CSO) Al Robichaud and the chief development officer (CDO) Jim Doherty. The restructuring comes at a time when the company plans the commercial launch of Zurzuvae for treating postpartum depression which is expected in late 2023. On 4 August, the FDA approved Zurzuvae’s use in women with postpartum depression while simultaneously issuing a complete response letter (CRL) for the treatment’s use in MDD. The CRL stated that the drug’s application did not provide substantial evidence of effectiveness in MDD and that ...
- Source: drugdu
- 153
- September 5, 2023
Bayer bets big on Kerendia’s potential to treat heart failure

Approved two summers ago for chronic kidney disease (CKD) associated with type 2 diabetes, Bayer’s Kerendia (finerenone) isn’t off to the flying start expected of a potential blockbuster. In the second quarter, sales of Kerendia reached 67 million euros ($73 million). For Bayer to achieve its ambitious peak sales target of 3 billion euros ($3.3 billion), it will have to expand the label of the nonsteroidal mineralocorticoid receptor antagonist (MRA). To get there, Bayer is making a big play in heart failure. Thursday, the company said it’s planning three new phase 3 trials in the indication, in addition to one that’s already underway. The new studies will evaluate Bayer’s medicine in roughly 9,000 new heart failure patients with reduced, mildly reduced and preserved ejection fraction. The REDEFINE-HF trial will investigate finerenone as a monotherapy in approximately 5,200 patients with an ejection fraction of greater than 40%. The FINALITY-HF trial will ...
- Source: drugdu
- 107
- September 5, 2023
Amgen’s $28B Horizon buyout cleared for takeoff after FTC, states settle

After months of legal wrangling, Amgen is free to go forward with its $27.8 billion buyout of Horizon Therapeutics. Friday, the U.S. Federal Trade Commission (FTC) said it reached a proposed consent order with Amgen to address the “potential competitive harm” that could result from the merger deal. Alongside the FTC, attorneys general from six states—California, Illinois, Minnesota, New York, Washington and Wisconsin—are moving to dismiss their injunction requests. The FTC first filed its antitrust lawsuit against Amgen in May in an attempt to block the sale. In its suit, FTC argued that Amgen could leverage its lucrative product portfolio to “entrench the monopoly positions” of Horizon’s thyroid eye disease drug Tepezza and the company’s gout treatment Krystexxa. For its part, Amgen has promised not to use that tactic with Horizon’s drugs. In a press release Friday, the company said it “has consistently stated to the FTC, the courts and ...
- Source: drugdu
- 111
- September 5, 2023
Hamilton Medical’s urgent ventilator notice deemed Class I recall by FDA

Dive Brief Hamilton Medical’s recall of ventilators for a software problem was designated Class I by the U.S. Food and Drug Administration, the agency wrote in a Monday notice. Hamilton contacted customers in June after learning that its C1, C2, C3 and T1 ventilators switch to “ambient state” if used in neonates for more than 91 days without a restart. In ambient state, the device sounds an alarm and no active ventilation is provided to patients. In light of the fault, which has caused 80 complaints but no injuries or deaths, Hamilton is asking users of its ventilators to regularly restart their devices. Dive Insight Hamilton sells mechanical ventilators for use in adults, children and infants. The problem that caused the Class I recall happens when the devices “are used for long-term ventilation in neonatal group.” If the ventilation time exceeds 91 days, the devices enter ambient state, causing them ...
- Source: drugdu
- 131
- September 4, 2023
Low-dose aspirin linked to 15% lower risk of type 2 diabetes in older adults

New research to be presented at this year’s Annual Meeting of the European Association for the Study of Diabetes (EASD) in Hamburg, Germany (2-6 October) shows that use of low dose (100mg daily) aspirin among older adults aged 65 years and older is associated with a 15% lower risk of developing type 2 diabetes. The authors, led by Professor Sophia Zoungas, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia, say the results show that anti-inflammatory agents such as aspirin warrant further study in the prevention of diabetes. The effect of aspirin on incident type 2 diabetes among older adults remains uncertain. This study investigated the randomised treatment effect of low dose aspirin on incident diabetes and fasting plasma glucose (FPG) levels among older adults. The authors did a follow-up study of the ASPREE trial – a double-blind, placebo-controlled trial of aspirin, the principal results of which were ...
- Source: drugdu
- 114
- September 4, 2023
Counterfeit pills involved in growing share of overdose deaths in the US, CDC study finds

By Deidre McPhillips, CNN Overdose deaths with evidence of counterfeit pill use became more than twice as common between the second half of 2019 and the end of 2021, according to a new CDC report. Tomas Nevesely/iStockphoto/Getty Images CNN — Overdose deaths reached record levels in the United States in recent years, and a new report shows that counterfeit pills are involved in a growing share of those deaths. The US Drug Enforcement Administration issued a public safety alert about a sharp increase of fake prescription pills laced with fentanyl and methamphetamine about two years ago. According to the agency, more than 9.5 million counterfeit pills were seized in 2021, more than the prior two years combined. A new report from the US Centers for Disease Control and Prevention captures the deadly consequences, tracking detailed accounts of deaths that were submitted to the CDC’s State Unintentional Drug Overdose Reporting System ...
- Source: drugdu
- 112
- September 4, 2023
Over-the-counter opioid overdose antidote Narcan to hit shelves next week, drugmaker says

By Meg Tirrell and Nadia Kounang, CNN Doctor explains new over-the-counter medicine that’s a ‘complete antidote to opioids’ CNN — The first over-the-counter naloxone, a drug used to reverse opioid overdose, will be available in retail stores and online as soon as next week, its manufacturer said Wednesday. The medicine, with the brand name Narcan, will have a suggested retail price of $44.99 per carton of two doses, maker Emergent BioSolutions said in a news release. It will be available initially in stores and online from retailers including Walgreens, Rite Aid, Walmart and CVS. The US Food and Drug Administration approved Narcan as an over-the-counter drug in March against a backdrop of record high deaths from opioid overdose, driven by powerful synthetic drugs like fentanyl. Narcan is a nasal spray version of naloxone, which can revive a person from an overdose within minutes. Nearly every state in the US has ...
- Source: drugdu
- 102
- September 4, 2023
Johnson & Johnson slashes price of tuberculosis drug Sirturo after relinquishing patent protections

Seven weeks after saying it would allow generic competition for drug-resistant tuberculosis (TB) treatment Sirturo (bedaquiline) in low- and middle-income countries (LMICs), Johnson & Johnson has slashed its own drug’s price in those markets. Under the new pricing structure, J&J’s drug will cost $130 for a six-month course in LMICs, a 55% discount from its prior price. Lupin also has reduced the cost of its generic version of bedaquiline by 33% to $194. The United Nations-backed Stop TB Partnership revealed the new prices on Wednesday. Last month, J&J said it would not enforce secondary patents on Sirturo in LMICs, paving the way for generic competition in many countries around the globe. The primary patent for Sirturo—which in 2012 became the first new TB drug approved in more than four decades—expired last month. But J&J had also patented improvements to its formulation, extending its protection for Sirturo into 2027. The reduced ...
- Source: drugdu
- 167
- September 4, 2023
Zerva acquires Acer Therapeutics to bolster rare disease portfolio

Zerva Therapeutics, formerly KemPharm, has announced a strategic acquisition of Acer Therapeutics to expand its rare therapies portfolio. The biggest Acer assets include the marketed rare therapy Olpruva (sodium phenylbutyrate formulation), and late-stage drug celiprolol. The acquisition is expected to be worth up to $91m in stock and cash payments, of which $76m is contingent upon milestone-based payments for Olpruva and celiprolol. Additionally, Zerva purchased Acer’s secured debt of more than $17m at a discounted value of $16.5m from its creditor, Nantahala Capital. The news caused Acer’s stock to skyrocket by 140% when the markets opened on 31 August. Zerva has a market cap of $165.25m, with a reported Q1 2023 revenue of $2.9m, as per the company’s financial report. Whilst Acer reported a loss of $8.1m in Q2 2023, as per the company’s Q2 financials. Olpruva is an oral suspension approved for the treatment of urea cycle disorders by ...
- Source: drugdu
- 105
- September 4, 2023
HHS calls for easing restrictions on marijuana, sending cannabis stocks higher

The U.S. Department of Health and Human Services has recommended reclassifying marijuana as a lower-risk drug, which would in turn ease restrictions on the budding business, a spokesperson for the Drug Enforcement Administration told CNBC on Wednesday. Marijuana is currently a Schedule I drug under the Controlled Substances Act, meaning it’s deemed to have no currently accepted medical use and a high potential for abuse. Despite being legalized for recreational use in nearly half of states, marijuana’s federal classification alongside drugs such as heroin and LSD has hindered the industry’s growth. After enjoying a sales surge during the Covid-19 pandemic, the industry is in free fall as investors turn away and capital dries up. The industry has also been barred from accessing most banking services, or from being traded across state lines, resulting in a glut of cannabis in many states and a drop in prices. A federal reclassification could ...
- Source: drugdu
- 100
- September 4, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.